Description

4-(5,7-Dioxo-5,7-Dihydro-6H-Pyrrolo[3,4-B]Pyrazin-6-Yl)Butanoic Acid is a high-purity heterocyclic carboxylic acid derivative, serving as a critical advanced pharmaceutical intermediate. Its value lies in its unique fused pyrrolopyrazine-dione structure, which is essential for constructing complex bioactive molecules in medicinal chemistry. This compound is primarily needed by research institutions and pharmaceutical companies engaged in the development of novel therapeutics, particularly for oncology and targeted drug discovery programs.

Application

• Pharmaceutical Intermediate: A key building block in the synthesis of complex drug candidates, particularly those targeting specific enzymes or protein-protein interactions.
• Medicinal Chemistry Research: Used in lead optimization and structure-activity relationship (SAR) studies to develop new pharmacophores with enhanced efficacy.
• Oncological Agent Development: Serves as a core scaffold for the research and development of potential small-molecule inhibitors for cancer treatment.
• Bioconjugation & Prodrug Synthesis: The butanoic acid moiety allows for further chemical modification, linking to carriers or creating prodrug formulations.
• Chemical Biology Probes: Utilized in the creation of molecular probes to study biological pathways and identify new therapeutic targets.
• High-Value Fine Chemical Synthesis: Employed in multi-step synthetic routes for producing specialized, high-margin fine chemicals.

Basic Information

Product Name	4-(5,7-Dioxo-5,7-Dihydro-6H-Pyrrolo[3,4-B]Pyrazin-6-Yl)Butanoic Acid
CAS No.	1351393-88-8
Molecular Formula	C10H9N3O4
Molecular Weight	235.20 g/mol
Synonyms	4-(5,7-Dioxo-6H-pyrrolo[3,4-b]pyrazin-6-yl)butanoic acid; 6-(3-Carboxypropyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-5,7-dione; 4-(5,7-Dioxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)butyric acid; Butanoic acid, 4-(5,7-dioxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)-; CAS 1351393-88-8; Pyrrolo[3,4-b]pyrazine-6-butanoic acid derivative
EINECS	Contact for details

Quality Control

Our 4-(5,7-Dioxo-5,7-Dihydro-6H-Pyrrolo[3,4-B]Pyrazin-6-Yl)Butanoic Acid is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation via NMR and MS, to ensure it meets the high standards required for pharmaceutical R&D. A comprehensive Certificate of Analysis (COA) detailing purity, impurities, and physical characteristics is provided with every shipment to guarantee traceability and consistency.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed after opening to minimize exposure to atmospheric moisture. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	Off-white to light yellow crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.